Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| WARD, AARON DUREL | 1 | — | — |
| JADHAO, SAMADHAN JAISING | 1 | 51.9% | +49.5% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +40.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571164 | PRPF31 VARIANT AND USES THEREOF | YU, DAVID TUYANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248523 | NUCLEIC ACID MOLECULE FOR TREATING BIETTI CRYSTALLINE DYSTROPHY AND USE THEREOF | WARD, AARON DUREL | — |
| 17756996 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756996 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | JADHAO, SAMADHAN JAISING | — |
| 17996786 | RHO-ADRP GENE EDITING-BASED METHODS AND COMPOSITIONS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1672 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571164 | PRPF31 VARIANT AND USES THEREOF | YU, DAVID TUYANG | — | §103 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18248523 | NUCLEIC ACID MOLECULE FOR TREATING BIETTI CRYSTALLINE DYSTROPHY AND USE THEREOF | WARD, AARON DUREL | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 10, 2023 |
| 17756996 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | JADHAO, SAMADHAN JAISING | 1672 | §101§103§112DPOther | Non-Final OA | — | Pending | Jan 24, 2023 |
| 17996786 | RHO-ADRP GENE EDITING-BASED METHODS AND COMPOSITIONS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial